Treatment of Hepatitis c by Using Direct-acting Antiviral - Trial NCT05372874
Access comprehensive clinical trial information for NCT05372874 through Pure Global AI's free database. This phase not specified trial is sponsored by Tanta University and is currently Not yet recruiting. The study focuses on Hepatitis C. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanta University
Timeline & Enrollment
N/A
May 06, 2022
Jul 30, 2022
Primary Outcome
Change in malondialdehyde (MDA) level.,Change in melatonin level.
Summary
Patients with hepatitis c showed increased level of oxidative stress. Increased level of
 serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA)
 which lead to disease progression. Chronic stress shunt tryptophan which is essential amino
 acid toward kynurenic pathway leading to lower level of serotonin and melatonin level.
 Currently, direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C
 virus (HCV).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05372874
Non-Device Trial